- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sonus completes EchoGen filing
The Food and Drug Administration has notified ultrasound contrast agent developer Sonus Pharmaceuticals of Bothell, WA, that its amended new drug application for EchoGen is complete. The news came after Sonus provided the FDA with the information the
The Food and Drug Administration has notified ultrasound contrast agent developer Sonus Pharmaceuticals of Bothell, WA, that its amended new drug application for EchoGen is complete. The news came after Sonus provided the FDA with the information the agency had asked for last month regarding EchoGens NDA amendment filing (SCAN 10/28/98).
Sonus executives had stated that the FDAs request for more information might delay EchoGens road to approval, but it appears that any delay will be insignificant in light of the FDAs acceptance of the filing. The FDA now has up to six months, beginning Oct. 19, to review EchoGens NDA.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
